– Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”). Topline data expected Q1 2026 – – Continues to advance CYB003, the Company’s proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive […]